Amylyx Pharmaceuticals, Inc. (AMLX) 10-Year Financial Performance & Capital Metrics

AMLX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAmylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $87M -77.1%
EBITDA -$314M -886.7%
Net Income -$302M -712.4%
EPS (Diluted) -4.43 -732.9%
Gross Margin 51.75% -44.5%
EBITDA Margin -359.19% -3528.8%
Operating Margin -360.22% -3635.1%
Net Margin -345.36% -2769.1%
ROE -100.88% -892.4%
ROIC -132.31% -1354.4%
Debt/Equity 0.01 +23.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)
✓Strong 5Y sales CAGR of 127.7%
✓Share count reduced 2.6% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y127.75%

3Y-

TTM-100.34%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM42.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.9%

ROCE

10Y Avg-357.67%

5Y Avg-357.67%

3Y Avg-62.61%

Latest-104.8%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.43M	650K	0	22.23M	380.79M	87.37M
Revenue Growth %	-	-0.54%	-1%	-	16.13%	-0.77%
Cost of Goods Sold+	11.9M	24.59M	0	2.99M	25.44M	42.16M
COGS % of Revenue	8.34%	37.84%	-	0.13%	0.07%	0.48%
Gross Profit+	-10.47M	-23.94M	0	19.24M	355.35M	45.22M
Gross Margin %	-7.34%	-36.84%	-	0.87%	0.93%	0.52%
Gross Profit Growth %	-	-1.29%	1%	-	17.47%	-0.87%
Operating Expenses+	13.55M	15.06M	82.69M	220.58M	316.54M	359.95M
OpEx % of Revenue	9.5%	23.17%	-	9.92%	0.83%	4.12%
Selling, General & Admin	3.08M	15.06M	38.93M	127.13M	188.36M	114.33M
SG&A % of Revenue	2.16%	23.17%	-	5.72%	0.49%	1.31%
Research & Development	11.9M	24.59M	44.04M	93.45M	128.19M	104.08M
R&D % of Revenue	8.34%	37.84%	-	4.2%	0.34%	1.19%
Other Operating Expenses	-1.43M	-24.59M	-285K	0	0	141.53M
Operating Income+	-13.55M	-39.01M	-82.69M	-201.34M	38.8M	-314.73M
Operating Margin %	-9.5%	-60.01%	-	-9.06%	0.1%	-3.6%
Operating Income Growth %	-	-1.88%	-1.12%	-1.43%	1.19%	-9.11%
EBITDA+	0	-39M	-82.64M	-200.85M	39.89M	-313.83M
EBITDA Margin %	-	-60.01%	-	-9.04%	0.1%	-3.59%
EBITDA Growth %	-	-	-1.12%	-1.43%	1.2%	-8.87%
D&A (Non-Cash Add-back)	13.55M	1K	52K	487K	1.09M	904K
EBIT	-12.44M	-39.01M	-82.69M	-201.34M	38.8M	-291.88M
Net Interest Income+	-1.1M	-2.27M	36K	4.29M	16.16M	13.81M
Interest Income	176K	14K	36K	4.29M	16.16M	13.81M
Interest Expense	1.28M	2.29M	0	0	0	0
Other Income/Expense	-162K	-3.27M	-5.24M	3.74M	15.49M	12.6M
Pretax Income+	-13.72M	-42.28M	-87.93M	-197.6M	54.3M	-302.14M
Pretax Margin %	-9.62%	-65.05%	-	-8.89%	0.14%	-3.46%
Income Tax+	0	0	0	774K	5.03M	-393K
Effective Tax Rate %	1.08%	1%	1%	1%	0.91%	1%
Net Income+	-14.82M	-42.28M	-87.93M	-198.38M	49.27M	-301.74M
Net Margin %	-10.39%	-65.05%	-	-8.92%	0.13%	-3.45%
Net Income Growth %	-	-1.85%	-1.08%	-1.26%	1.25%	-7.12%
Net Income (Continuing)	-13.72M	-42.28M	-87.93M	-198.38M	49.27M	-301.74M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.26	-0.79	-1.52	-2.98	0.70	-4.43
EPS Growth %	-	-2.04%	-0.92%	-0.96%	1.23%	-7.33%
EPS (Basic)	-0.26	-0.79	-1.52	-2.98	0.73	-4.43
Diluted Shares Outstanding	56.47M	56.47M	57.86M	66.51M	69.99M	68.14M
Basic Shares Outstanding	56.47M	56.47M	57.86M	66.51M	67.23M	68.14M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.2M	13.64M	104.95M	382.13M	464.67M	189.43M
Cash & Short-Term Investments	3.06M	12.88M	96.12M	346.94M	371.36M	176.5M
Cash Only	3.06M	12.88M	50.19M	62.53M	170.2M	77.39M
Short-Term Investments	0	0	45.93M	284.42M	201.16M	99.11M
Accounts Receivable	0	0	0	15.31M	40.05M	447K
Days Sales Outstanding	-	-	-	251.31	38.39	1.87
Inventory	0	0	0	9.77M	38.32M	0
Days Inventory Outstanding	-	-	-	1.19K	549.82	-
Other Current Assets	26K	0	3.44M	10.11M	14.93M	12.48M
Total Non-Current Assets+	18K	465K	663K	9.32M	52.79M	4.2M
Property, Plant & Equipment	0	151K	474K	8.13M	6.41M	2.73M
Fixed Asset Turnover	-	4.30x	-	2.73x	59.40x	31.98x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	189K	0	0	0	0
Other Non-Current Assets	18K	125K	189K	1.19M	46.38M	1.47M
Total Assets+	3.22M	14.1M	105.61M	391.45M	517.45M	193.63M
Asset Turnover	0.44x	0.05x	-	0.06x	0.74x	0.45x
Asset Growth %	-	3.38%	6.49%	2.71%	0.32%	-0.63%
Total Current Liabilities+	4.53M	7.33M	17.4M	46.61M	82.04M	28.41M
Accounts Payable	2.19M	3.61M	4.37M	6.26M	22.06M	2.94M
Days Payables Outstanding	67.33	53.62	-	763.05	316.51	25.45
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	652K	0	4.28M	15.23M	40.93M	9.99M
Current Ratio	0.71x	1.86x	6.03x	8.20x	5.66x	6.67x
Quick Ratio	0.71x	1.86x	6.03x	7.99x	5.20x	6.67x
Cash Conversion Cycle	-	-	-	679.61	271.7	-
Total Non-Current Liabilities+	24.05M	73.5M	239.39M	4.24M	1.98M	463K
Long-Term Debt	14.93M	1.43M	0	0	0	0
Capital Lease Obligations	0	0	0	4.24M	1.98M	463K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	9.11M	72.06M	239.39M	0	0	0
Total Liabilities	28.58M	80.83M	256.78M	50.85M	84.02M	28.87M
Total Debt+	14.93M	1.43M	0	6.28M	4.24M	1.98M
Net Debt	11.87M	-11.45M	-50.19M	-56.25M	-165.96M	-75.41M
Debt / Equity	-	-	-	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	0.11x	-
Net Debt / EBITDA	-	-	-	-	-4.16x	-
Interest Coverage	-10.62x	-17.05x	-	-	-	-
Total Equity+	-25.36M	-66.72M	-151.17M	340.61M	433.43M	164.76M
Equity Growth %	-	-1.63%	-1.27%	3.25%	0.27%	-0.62%
Book Value per Share	-0.45	-1.18	-2.61	5.12	6.19	2.42
Total Shareholders' Equity	-25.36M	-66.72M	-151.17M	340.61M	433.43M	164.76M
Common Stock	1K	1K	1K	7K	7K	7K
Retained Earnings	-25.63M	-67.91M	-155.84M	-354.22M	-304.95M	-606.69M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	-72.06M	9K	-86K	197K	-92K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.69M	-36.7M	-74.8M	-179.87M	11.92M	-167.65M
Operating CF Margin %	-7.49%	-56.46%	-	-8.09%	0.03%	-1.92%
Operating CF Growth %	-	-2.43%	-1.04%	-1.4%	1.07%	-15.07%
Net Income	-13.72M	-42.28M	-87.93M	-198.38M	49.27M	-301.74M
Depreciation & Amortization	0	1K	52K	487K	1.09M	904K
Stock-Based Compensation	0	243K	3.14M	21.71M	0	33.04M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	-475K	2.74M	5.35M	-2.06M	27.22M	145.99M
Working Capital Changes	3.5M	2.6M	4.59M	-1.64M	-65.66M	-45.83M
Change in Receivables	0	0	-144K	-15.31M	-24.74M	39.6M
Change in Inventory	0	0	0	-9.77M	-73.13M	-9.25M
Change in Payables	1.28M	1.42M	670K	1.85M	15.88M	-19.1M
Cash from Investing+	0	-151K	-46.41M	-238.99M	92.05M	75.65M
Capital Expenditures	0	-151K	-353K	-2.53M	-1.24M	-157K
CapEx % of Revenue	-	0.23%	-	0.11%	0%	0%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-236.46M	0	-36.2M
Cash from Financing+	668K	46.82M	158.51M	431.79M	3.54M	348K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	48K	-2.39M	-658K	-3.31M	-1.78M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-10.69M	-36.85M	-75.15M	-182.4M	10.68M	-167.8M
FCF Margin %	-7.49%	-56.69%	-	-8.2%	0.03%	-1.92%
FCF Growth %	-	-2.45%	-1.04%	-1.43%	1.06%	-16.71%
FCF per Share	-0.19	-0.65	-1.30	-2.74	0.15	-2.46
FCF Conversion (FCF/Net Income)	0.72x	0.87x	0.85x	0.91x	0.24x	0.56x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	27K	0	708K

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-209.43%	12.73%	-100.88%
Return on Invested Capital (ROIC)	-	-	-	-363.87%	10.55%	-132.31%
Gross Margin	-734.43%	-3683.69%	-	86.54%	93.32%	51.75%
Net Margin	-1038.99%	-6504.62%	-	-892.38%	12.94%	-345.36%
Debt / Equity	-	-	-	0.02x	0.01x	0.01x
Interest Coverage	-10.62x	-17.05x	-	-	-	-
FCF Conversion	0.72x	0.87x	0.85x	0.91x	0.24x	0.56x
Revenue Growth	-	-54.42%	-100%	-	1612.94%	-77.06%

Frequently Asked Questions

Growth & Financials

Amylyx Pharmaceuticals, Inc. (AMLX) reported $-0.7M in revenue for fiscal year 2024. This represents a 147% decrease from $1.4M in 2019.

Amylyx Pharmaceuticals, Inc. (AMLX) saw revenue decline by 77.1% over the past year.

Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $149.3M for fiscal year 2024.

Dividend & Returns

Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity (ROE) of -100.9%. Negative ROE indicates the company is unprofitable.

Amylyx Pharmaceuticals, Inc. (AMLX) had negative free cash flow of $154.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener